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Mast cells are widely distributed throughout the body,
being preferentially localized at host–environment
interfaces. They have long been known as major
effector cells in IgE-mediated allergic responses.
However, accumulating evidence has provided many
new insights into their functions. They are now known
to be involved in diverse pathological processes, for
example, innate and adaptive immunity. Utility of
mast cell-deficient mice and mast cell-knock-in mice
has provided powerful models to demonstrate com-
pelling evidence for their in vivo relevance. Conver-
sely, primary cultures of tissue-derived mast cells
provide excellent models for in vitro studies of
functions at both cellular and molecular levels.
Because mast cells exhibit phenotypical and func-
tional heterogeneity in different anatomical sites, it is
important to obtain tissue-specific mast cells to clarify
their function in tissue. In this regard, researchers
have established several methods to prepare mast
cells from different tissues, which are technically
difficult to obtain at high purity and yield. To over-
come these difficulties, we have developed a primary
culture system to obtain large numbers of mast cells at
high purity from murine fetal skin. In this review, we
describe characteristics of such mast cells and their
utility in mast cell biology.
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INTRODUCTION
Over the past decade, most immunologists might have paid
less attention to mast cells as important players in innate and
acquired immunity and considered mast cells only as effector
cells that induce acute hypersensitivity responses via IgE-
mediated mechanisms. We believe that this notion has been
extensively revised for such immunologists, and even for
researchers handling mast cells, by the surprising findings
published in the last decade or so. We now know that mast
cells are involved in a huge array of pathological processes,
for example, innate and adaptive immunity, tolerance
induction, immune suppression, autoimmunity, chronic
inflammation, tissue remodeling/wound repair, tumor pro-
gression, and detoxification. For a detailed overview on these
subjects, the reader is referred to several recent excellent
reviews (Marshall, 2004; Galli et al., 2005; Christy and
Brown, 2007; Metz and Maurer, 2007; Metz et al., 2007;
Galli and Tsai, 2008). It seems that mast cells have
implications for a wide variety of host defense mechanisms
in health and disease. Considering the expansion of the
number of mast cell studies, easier access to mast cells may
facilitate discovery of new functions in unexpected fields. In
this review, we discuss the development of a mast cell culture
system, which we recently developed, and testing of its utility
for exploring undiscovered functions of mast cells.
BRIEF OVERVIEW OF MAST CELL BIOLOGY: FOCUS ON
SUBPOPULATIONS
Mast cells have long been known as major effector cells in
acute allergic responses because the cross-linking of IgE-
bound, high-affinity IgE receptors (FceRI) on mast cells by
multivalent antigens triggers the immediate degranulation
and subsequent release of a wide variety of chemical and
lipid mediators from these cells (Rivera and Gilfillan, 2006).
In addition to this rapid host reaction, mast cells are also
activated by many other stimuli (for example, chemicals,
toxic substances, infectious microbes, cytokines, growth
factors, and hormones) with or without degranulation,
leading to the differential release of multiple mediators
(Marshall, 2004; Galli et al., 2005; Theoharides et al., 2007).
Thus, mast cells have the potential to influence a huge array
of host defense reactions.
For host responses involving the function of mast cells, the
anatomical location of mast cells seems to be essential. Mast
cells are widely distributed throughout the body, preferen-
tially in close proximity to epithelial surfaces (for example,
skin, respiratory system, and gastrointestinal tracts) where
they reside around blood vessels and peripheral nerves. They
are a progeny of bone marrow-derived hematopoietic cells
(Kitamura et al., 1977). Small numbers of committed mast
cell progenitors circulate in the blood and migrate to tissues,
where their terminal maturation is accomplished under the
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influence of their final microenvironment (Gurish and Boyce,
2006). Committed mast cell progenitors reside at special
anatomical sites (for example, intestine and hair follicles) and
locally proliferate with terminal maturation (Kumamoto et al.,
2003; Gurish and Boyce, 2006). Proliferation, terminal
differentiation, and survival of resident mast cells require
growth factors, such as IL-3, stem cell factor, and/or other
factors (Gurish and Boyce, 2006). At least two types of mast
cells have been historically identified in rodents based on
their morphological, biochemical, and functional properties
(Kitamura, 1989). They were originally classified into
connective tissue-type mast cells (CTMC) and mucosal mast
cells. CTMC reside in the dermis of skin, submucosal
connective tissues of the respiratory tract, joint synovia, and
peritoneum. Mucosal mast cells reside in the mucosa of the
gastrointestinal tract and in the lamina propria of the
respiratory tract. Both cell types differ in profiles of (1)
protease and glycosaminoglycan contents of their granules,
(2) lipid-mediator production, and (3) responsiveness to
polybasic compounds (for example, compound 48/80) and
substance P (Marshall, 2004). Therefore, to study roles played
by mast cells at any anatomical site, it is essential to
characterize the phenotype and function of mast cells
isolated from those given anatomical sites.
With respect to mast cell sources for studies in mice,
peritoneal mast cells and bone marrow-derived mast cells
(BMMC) have been widely used. However, both cell types
have some pitfalls. BMMCs are often regarded as in vitro
equivalent of mucosal mast cells but they are actually
immature mast cells. Mouse peritoneal mast cells represent
CTMC, but it is relatively difficult to obtain large numbers at
high purity from peritoneal lavage fluid. It is even more
difficult and laborious to isolate large numbers of mast cells at
high purity from adult skin, although this method has been
established (He et al., 1990).
ESTABLISHMENT AND EVALUATION OF FETAL
SKIN-DERIVED MAST CELLS
The technical breakthrough to obtain a large number of skin
mast cells at high purity was made by Yamada et al. (2003).
They developed a new method to easily obtain relatively
large numbers of fetal skin-derived mast cells (FSMC) at high
purity from day 14 to day 16 murine fetal skin. Single cell
suspensions were prepared from excised day 14 to day 16
fetal trunk skin specimens by limited trypsinization. After
red blood cell lysis and extensive washing, crude cells
(5104 cells per ml) were cultured in complete RPMI in the
presence of mast cell growth factors, murine recombinant IL-
3 (10 ngml1), and stem cell factor (10 ngml1). Non-
adherent cells and loosely adherent cells were collected 14
days after this initial culture (without changing the culture
medium), and enriched for mast cells by density gradient
centrifugation. The resulting mast cell preparations (about
7106 cells per fetus), containing 496% CD45þ CD117þ
(c-kitþ ) cells, were used as FSMC without further purification
(Figure 1).
Yamada et al. (2003) found that about 5% of fetal skin
crude cells contained CD45þ CD49bþ CD117þ FceRI
cells, which could proliferate in response to stem cell factor.
They considered these freshly isolated cells to be immature
mast cells because the FceRI-positive cell population
gradually increased the longer they were in culture. After
14 days of culture, virtually all the cells expressed high levels
of functional FceRI and thus had differentiated into mature
mast cells. Compatible with these findings, Meindl et al.
(2006) recently reported that the majority of lineage-negative
CD45þ dermal cells from newborn and adult mouse skin
were mast cell precursors. Therefore, fetal skin may provide a
more suitable source than older murine skin to obtain
abundant precursors of skin-derived mast cells.
FSMCs maintained a similar surface phenotype to skin
mast cells derived from adult mice. In addition, FSMC had
many characteristic features of CTMC. Those include: (1)
higher contents of histamine and heparin than BMMC, (2)
their capacity to degranulate in response to compound
48/80 and substance P, (3) the high expression of CD49b
(Table 1). Thus, FSMC, which represent CTMC, serve as an
excellent model for in vitro studies of skin-derived mast cells
or CTMC.
NEW PUTATIVE FUNCTIONS OF MAST CELLS:
CONTRIBUTIONS OF FSMC
Toll-like receptors on mast cells
Toll-like receptors (TLRs) serve as sensors against pathogens
that invade the host by recognizing pathogen-associated
molecular patterns (Takeda et al., 2003). Each TLR recognizes
a distinct ligand, as shown by TLR-knockout mice. TLRs
have been extensively studied in the context of their
expression by antigen-presenting cells (that is, dendritic cells
Fetal skin








(5 × 104 cells ml–1)
(~7 x 106 cells per fetus)
Figure 1. Generation of fetal skin-derived mast cells (FSMC). Single cell
suspensions derived from fetal skin are cultured at a low cell density in the
presence of mast cell growth factors for 2 weeks without changing the
medium. Non-adherent and loosely adherent cells are collected and enriched
for mast cells by density gradient centrifugation. The resulting mast cell
preparation (about 7 106 cells per fetus) contains4 96% CD45þ CD117þ
cells, which are used as FSMC without further purification.
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and macrophages), which induce innate immunity and
subsequently acquired immunity (Kaisho and Akira, 2006).
Although TLR2 and TLR4 expression and function of mast
cells in response to bacterial products have been well
documented (Marshall, 2004; Stelekati et al., 2007), expres-
sion profiles of other TLRs and their functions on mast cells
remain relatively unclear. Working with FSMC and BMMC,
Matsushima et al. (2004b) examined TLR mRNA expression
profiles and functions. TLR2 and TLR4 mRNAs were detected
in both mast cell types at comparable levels. However, TLR3,
TLR7, and TLR9 mRNAs were expressed by FSMC at higher
levels than by BMMC (Table 1). Reflecting the differences of
their TLR expression profiles, FSMC, but not BMMC,
produced inflammatory cytokines (tumor necrosis factor-a
and IL-6) and chemokines (RANTES, macrophage inflamma-
tory protein-1a and -2, and MIP-2) without degranulation in
response to poly(I:C), R-848, and CpG oligodeoxynucleotide,
which are TLR3, TLR7, and TLR9 ligands, respectively.
Because TLR3, TLR7, and TLR9 are known to recognize
products associated with viruses, these in vitro findings may
have implications for roles of these TLRs expressed by mast
cells in viral infections. One may speculate that mast cells
enhance local infiltration of a variety of immune cells by
releasing inflammatory cytokines and chemokines upon viral
as well as bacterial infections, presumably by being involved
in the transition of innate immune responses to acquired
immune responses. Further studies will be required to
determine the involvement of mast cells in viral infections
using mast cell-deficient mice and their reconstitution with
TLR-deficient mast cells.
Endothelin-1 on mast cells
Endothelin-1 (ET-1) was originally discovered as a potent
vasoconstrictive peptide derived from endothelial cells
(Yanagisawa et al., 1988). Earlier studies focused on its
potential as a mediator in the cardiovascular system. For
instance, ET-1 was found to be involved in a variety of
vascular diseases, including essential systemic hypertension,
pulmonary hypertension, coronary vasospasm, and cardiac
Table 1. Characteristic profiles of FSMC and BMMC1
FSMC BMMC





Major proteoglycans Heparin Chondroitin
sulfate
Histamine content +++ +
Granule proteases +++ +
Degranulation induced by
Ionomycin + +
Compound 48/80 + 
Substance P + 
ET-1 + 
OPN  











TLR expression TLR1, 2, 3, 4, 6, 7,
9
TLR2, 4, 6
Spontaneous ET-1  
ET-1 induced by
Ionomycin + 
TLR ligands2 + 
Spontaneous OPN + 
OPN induced by
Ionomycin + +
IgE cross-linking + +
Table 1. Continued
FSMC BMMC
OPN augmented or induced by
TLR ligands3  
BMMC, bone marrow-derived mast cells; ET-1, endothelin-1; FSMC, fetal
skin-derived mast cells; LPS, lipopolysaccharide; ND, not determined;
ODN, oligodeoxynucleotide; OPN, osteopontin; PGN, peptidoglycan;
TLR, Toll-like receptor.
All photographs were reproduced with the permission of the publisher
(from Yamada et al., 2003).
1Data presented in this table are summarized from the following four
papers: Matsushima et al. (2004a, b), Nagasaka et al. (2008), and Yamada
et al. (2003).
2TLR ligands include PGN for TLR2, poly(I:C) for TLR3, LPS for TLR4, and
CpG ODN for TLR9.
3TLR ligands include poly(I:C) for TLR3, LPS for TLR4, R848 for TLR7, and
CpG ODN for TLR9.
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failure (Nambi et al., 2001; Schiffrin, 2001; Taddei et al.,
2001). Subsequent studies revealed that ET-1 was also
involved in the pathogenesis of non-vascular diseases,
including inflammatory diseases (for example, asthma and
allergic rhinitis) and fibrotic diseases (for example, systemic
sclerosis, pulmonary fibrosis, and hepatic fibrosis) (Van-
cheeswaran et al., 1994; Rockey and Chung, 1996; Goldie
and Henry, 1999; Hocher et al., 2000; Mullol and Picado,
2000).
Working with FSMC (Matsushima et al., 2004a), we found
that ET-1 was able to (a) induce degranulation by FSMC via
ETA in a dose-dependent manner (10
8 to 106 M), (b)
significantly augment degranulation by IgE-sensitized FSMC
using the above dose ranges, (c) at its lower concentration
(1010 M), significantly suppress degranulation induced by
FceRI aggregation, (d) induce proinflammatory cytokine
production (tumor necrosis factor-a and IL-6), (e) significantly
enhance VEGF production and transforming growth factor-b1
mRNA expression, and (f) ET-1 was able to be produced by
FSMC in response to TLR ligands (that is, TLR2, TLR3, TLR4,
and TLR9 ligands) (Table 1). On the contrary, BMMC did not
respond to ET-1 and did not produce ET-1 in response to
these TLR ligands. These findings indicate that multi-
functional effects of ET-1 on mast cells may participate in
the pathogenesis of a wide array of diseases, including
allergic, inflammatory, angiogenic, and fibrotic diseases.
Our findings lacked in vivo relevance of ET-1-induced
activation and degranulation by mast cells. Soon thereafter,
Maurer et al.made a landmark discovery that linked ET-1 and
sepsis. They found that ET-1-dependent degranulation by
mast cells resulted in protease release that degraded ET-1 and
reduced its levels. This release protected normal mice, but
not mast cell-deficient mice, from the lethal effects of
peritoneal sepsis that was induced after an intraperitoneal
injection of ET-1 (Maurer et al., 2004). Because ET-1 has high
homology (470%) to sarafotoxins, the most potent toxic
components of certain venoms, they hypothesized that mast
cells might also be protective in envenomation. Indeed, Metz
et al. (2006b) elegantly demonstrated that mast cells could
defend against toxins of snakes or bees by releasing proteases
(mainly carboxypeptidase A) that cleave and detoxify those
toxins, thus providing protection from the pathological
consequences of snake bites or bee stings. This discovery
surprised us because mast cells were commonly considered
to participate in anaphylactic shock by elaborating a wide
array of mediators leading to tissue damage. Detoxification is
thus a novel aspect of innate immunity played by mast cells.
Another in vivo relevance of the ET-1 system in mast cells
was recently reported by the same group (Metz et al., 2006a).
They found that ET-1 potently induced degranulation by mast
cells that were purified from the ear skin of adult mice in vitro
and that ET-1 induced skin inflammation in vivo by activating
skin-resident mast cells. Both activations were mediated via
ETA receptors. The in vitro data were consistent with our data
that ET-1 induced degranulation by FSMC via ETA receptors,
which supports the notion that FSCM represent skin-derived
mast cells. In addition, UVB-mediated increase of ET-1
levels in the skin was associated with UV-induced skin
inflammation evoked, in part, by the activation of mast cells
via ligation of ET-1 to ETA receptors on mast cells. Therefore,
the ET-1 system in mast cells serves as a double-edged sword
depending on physiological and pathological conditions.
Osteopontin on mast cells
Osteopontin (OPN) is an arginine–glycine–aspartate (RGD)-
containing glycoprotein, which participates in bone remodel-
ing (Denhardt et al., 2001), wound healing (Liaw et al.,
1998), dystrophic calcification, and coronary restenosis
(Rangaswami et al., 2006). Immunologists found that it is
expressed and functions in many immune cell types
(Rangaswami et al., 2006). Those include macrophages,
activated T cells, myeloid dendritic cells, plasmacytoid
dendritic cells, and natural killer T (NKT) cells; thus it can
exhibit many potential effects on the immune system
(O’Regan et al., 2000; Diao et al., 2004; Renkl et al., 2005;
Shinohara et al., 2005, 2006). For instance, OPN plays an
important role in efficient TH1 immune responses in many
experimental settings. Ashkar et al. (2000) demonstrated that
OPN contributed to a host defense against pathogens (for
example, herpes simples) and to the TH1-dependent granu-
loma formation by a TH1-driving cytokine, IL-12, secreted by
macrophages. OPN induced maturation of myeloid dendritic
cells toward a TH1-promoting phenotype (Renkl et al., 2005).
T-bet-dependent OPN expression by activated T cells skewed
CD4þ and CD8þ T cells toward TH1 and Tc1 CD8
þ T cells,
respectively (Shinohara et al., 2005). In a more recent report,
intracellular OPN in plasmacytoid dendritic cells regulated
their IFN-a production, thus being involved in TH1 immunity
to viral infection (Shinohara et al., 2006). In addition to its
function as a TH1 cytokine, OPN also exerts its effects on
inflammatory processes. For example, NKT cell-derived OPN
is a major mediator of Concanavalin A-induced hepatitis by
augmenting NKT cell activation and triggering neutrophil
infiltration (Diao et al., 2004). OPN is also involved in
autoimmune diseases, including multiple sclerosis and its
animal model (Chabas et al., 2001; Jansson et al., 2002), and
rheumatoid arthritis and its animal model (Yumoto et al.,
2002; Yamamoto et al., 2003; Xu et al., 2005). Thus, OPN is
now believed to participate in complex processes of a wide
array of inflammatory and immune diseases. Mast cells are
also equipped with potent capacities to participate in a wide
array of pathological processes (for example, innate and
adaptive immune responses, autoimmune responses, tissue
remodeling/wound repair, and tumor progression by releas-
ing a wide array of mediators; Benoist and Mathis, 2002;
Gruber, 2003; Levi-Schaffer and Piliponsky, 2003; Marshall,
2004; Theoharides and Conti, 2004; Galli et al., 2005). We
hypothesized that mast cells may produce OPN, which may
affect their function and participate in such diverse patholo-
gical processes. To this end, we recently examined effects of
OPN on FSMC, and BMMC and OPN production by these
mast cell types (Nagasaka et al., 2008). OPN was found to (1)
be spontaneously produced by FSMC and be inducible
in BMMC in response to stimuli (for example, FceRI
aggregation and ionomycin), (2) significantly augment
mast cell degranulation by FceRI aggregation, and (3)
www.jidonline.org 1123
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promote chemotaxis of mast cells (Table 1). Our results
have also revealed that OPN secreted by FSMC was
biologically active and had no effect on the development
of FSMC. Conversely, ample experimental evidence of
the involvement of OPN in the pathogenesis of many
inflammatory and immune diseases may provide a key to
elucidate a link between mast cells and those diseases.
However, further studies will be required to define the role of
OPN as a pleiotropic mediator that regulates many functions
of mast cells, presumably by participating in multiple aspects
of inflammatory and immune diseases. In addition, based
on our findings, Bulfone-Paus and Paus (2008) recently
discussed why this newly discovered property of mast cell-
derived OPN accounts for the recent concept that OPN may
serve as a multipurpose environmental damage-response
protein.
Other evidence of utility of FSMC for mast cell research
We hope that FSMC will become more popular for mast cell
studies because there are no technical difficulties in obtaining
large numbers at high purity. Indeed, Oki et al. (2006) used
FSMC as a mast cell type to investigate integrin aIIbb3
expression. Another advantage of FSMC is that we can
generate cells from gene knockout mice even if these mice
result in neonatal lethality. In other words, we can generate
certain gene-deficient FSMC from intercrossing heterozygous
mice. Using this technique, Feyerabend et al. (2006) found
that C5-epimerase-deficient FSMC distorted the heparin O-
sulfation pattern, providing new information of heparin
biosynthesis in mast cells. Because we can reconstitute
dermal mast cells in mast cell-deficient mice several weeks
after FSMCs are intradermally injected (unpublished data),
this reconstitution method may provide a faster means to
investigate in vivo functions of particular gene-deficient
dermal mast cells.
Concluding remarks
Galli et al. (2005) considered mast cells as ‘‘tunable’’ effector
and immunoregulatory cells. Mast cells may be central for
initiating, tuning, and regulating inflammatory and immune
responses observed in complex tissue reactions in health and
disease. These new findings obtained from mouse systems
keep providing new ideas to test their relevance in humans
and conceptual frameworks to develop new agents to
enhance or silence mast cell functions for human health.
We hope that FSMC will provide an easily accessible tool for
a broad range of immunologists to discover novel roles
played by mast cells, especially CTMC, in their research field.
Such approaches may ultimately provide new, unexpected
ideas to control many diseases by manipulating mast cell
functions.
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